Table 4.

Adverse events related to different characteristics of the study subjects.

Adverse events	Present	Absent	X2, p-value
Age: <18 years (n = 69) 18–60 years (n = 40) >60 years (n = 14)	8 (11.6) 4 (10) 2 (14.3)	61 (88.4) 36 (90) 12 (85.7)	0.196; 0.90
Concomitant vaccines: PCECV (n = 59) PVRV (n = 64)	8 (13.5) 6 (9.4)	51 (86.5) 58 (90.6)	0.533; 0.46
Site of HRIG administration: Local (n = 99) Both local and Systemic (n = 24)	10(10.1) 4 (16.6)	89 (89.9) 20 (83.4)	0.826; 0.36
Dose of HRIG administration:
0.7–1.9 ml (n = 50)	4 (80)	46 (20)	12.36;
2–3.1 ml (n = 68)	7 (10.3)	61 (89.7)	0.002
3.2–7.4 ml (n=5)	3 (60)	2 (40)
Timing of adverse events:
Immediate	14	109

Figures in parenthesis indicates percentages; HRIG: human rabies immunoglobulin; X²  = chi-square value.